claseprubart   Click here for help

GtoPdb Ligand ID: 14583

Synonyms: DNTH-103 | DNTH103 | IgG4-MAB39 [US12110344] | MAB39 [US12110344]
Immunopharmacology Ligand
Compound class: Antibody
Comment: Claseprubart (DNTH103) is a long-acting monoclonal antibody that selectively inhibits the active form of the C1s (complement component 1s) protein in the classical complement pathway.
Peptide sequences for the heavy and light chains of claseprubart are 100% matches for sequences for MAB39 that are claimed in patent US12110344B2 [1].
Click here for help
No information available.
Summary of Clinical Use Click here for help
Claseprubart (DNTH103) was progressed as a clinical candidate for the treatment of severe autoimmune and neuromuscular diseases. Studies were initiated for generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy. The FDA granted orphan designation for the treatment of myasthenia gravis in May 2026 [2].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT06282159 A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC) Phase 2 Interventional Dianthus Therapeutics
NCT06537999 A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy Phase 2 Interventional Dianthus Therapeutics
NCT06858579 A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE) Phase 3 Interventional Dianthus Therapeutics
NCT07647510 A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE) Phase 3 Interventional Dianthus Therapeutics